Short Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Decreases By 23.8%

Quince Therapeutics, Inc. (NASDAQ:QNCX) saw a large decrease in short interest in November. As of November 15th, there was short interest totalling 1,790,000 shares, a decrease of 23.8% from the October 31st total of 2,350,000 shares. Currently, 5.5% of the company’s stock are sold short. Based on an average trading volume of 527,400 shares, the days-to-cover ratio is currently 3.4 days.

Analysts Set New Price Targets

Several research firms recently weighed in on QNCX. Maxim Group began coverage on Quince Therapeutics in a report on Thursday, November 7th. They issued a “buy” rating and a $6.00 target price for the company. RODMAN&RENSHAW raised shares of Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Rodman & Renshaw assumed coverage on Quince Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $11.00 price objective on the stock. Finally, EF Hutton Acquisition Co. I raised Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd.

Quince Therapeutics Trading Up 1.0 %

Shares of QNCX stock opened at $2.04 on Friday. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.45. The firm’s fifty day simple moving average is $1.20 and its 200 day simple moving average is $0.90. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC increased its position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 339,125 shares of the company’s stock after buying an additional 66,170 shares during the quarter. Geode Capital Management LLC owned 0.78% of Quince Therapeutics worth $263,000 at the end of the most recent quarter. Institutional investors and hedge funds own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.